SCHEMBL351489

SCHEMBL351489

Cc1ccc(S(=O)(=O)C(C)(C)c2nc(-c3cc(C(C)(C)C)nn3C)co2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.37
KDM4E B2RXH2 2/20 0.35
GRN P28799 1/20 0.35
SORT1 Q99523 1/20 0.35
MAPK14 Q16539 2/20 0.33
MAPT P10636 2/20 0.32
ALDH1A1 P00352 2/20 0.32
POLB P06746 2/20 0.32
CYP2C9 P11712 2/20 0.32
PTGS2 P35354 2/20 0.32
PDPK1 O15530 2/20 0.31
PTGES O14684 1/20 0.31
HDAC3 O15379 1/20 0.31
CA12 O43570 1/20 0.31
PDE5A O76074 1/20 0.31
ABCB11 O95342 1/20 0.31
MT-CO2 P00403 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL350334 0.91 CNR2 (0.36) CNR2KDM4EGRNSORT1ALDH1A1
SCHEMBL351891 0.91 CNR2 (0.47) CNR2KDM4EGRNSORT1MAPK14
SCHEMBL353288 0.80 CNR2 (0.37) CNR2KDM4EGRNSORT1MAPK14
SCHEMBL10146115 0.80 KDM4E (0.38) KDM4EGRNSORT1MAPK14MAPT
SCHEMBL351482 0.77 CNR2 (0.32) CNR2KDM4EGRNSORT1
SCHEMBL13618548 0.76 KDM4E (0.36) KDM4EGRNSORT1
SCHEMBL1250777 0.75 ALDH1A1 (0.34) CNR2MAPK14ALDH1A1MEN1KMT2A
SCHEMBL1250775 0.75 MEN1 (0.37) CNR2MAPK14MAPTALDH1A1LMNA
SCHEMBL10147904 0.75 CNR2 (0.31) CNR2MAPK14
SCHEMBL351110 0.74 CNR2 (0.39) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418207-A1 Sulfone compounds which modulate the CB2 receptor Boehringer Ingelheim International GmbH (DE) 2012-02-15 EP claimed
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 US claimed
EP-2418207-A1 Sulfone compounds which modulate the CB2 receptor Boehringer Ingelheim International GmbH (DE) 2012-02-15 EP disclosed
EP-2418207-A1 Sulfone compounds which modulate the CB2 receptor Boehringer Ingelheim International GmbH (DE) 2012-02-15 EP disclosed
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 US disclosed
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 US disclosed
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-19 US disclosed
WO-2009140089-A2 SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015988-A1 Sulfone Compounds Which Modulate The CB2 Receptor CNR2, CNR1, TRPV1 CNR2 1/4885KDM4E 2157/4885GRN 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.